Revenue has contracted significantly to $12.4M in 2026Q3, while gross margins have eroded from a 77.9% peak in 2024Q2 to 55.1% due to competitive pricing pressures.
| Metric | TTM | Jun'25 | Jun'24 | Jun'23 | Jun'22 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Aug'14 | Aug'13 | Aug'12 | Aug'11 | Aug'10 | Aug'09 | Aug'08 | Aug'07 |
|---|
| Sales/Revenue | 56.6M | 66.38M | 65.18M | 107.4M | 96.67M | 65.63M | 27.63M | 7.32M | 3.66M | 3.22M | 2.56M | 261.78K | 58.93K | 1.75K | 1.75K | 0 | 0 | 1.75K | 0 | 0 |
| Revenue Growth % | -18.24% | 1.84% | -39.31% | 11.1% | 47.29% | 137.52% | 277.47% | 100.01% | 13.61% | 25.72% | 878.85% | 344.23% | 3267.37% | 0% | - | - | -100% | - | - | - |
| Cost of Goods Sold | 21.22M | 20.55M | 16.13M | 40.77M | 46.39M | 36.43M | 8.28M | 2.2M | 2.05M | 1.42M | 957.08K | 88.11K | 0 | -48.25K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 30.96% | 24.74% | 37.96% | 47.98% | 55.51% | 29.97% | 30.08% | 56.03% | 44% | 37.35% | 33.66% | - | -2757.14% | - | - | - | - | - | - |
| Gross Profit | 35.38M | 45.83M | 49.05M | 66.63M | 50.28M | 29.2M | 19.35M | 5.12M | 1.61M | 1.8M | 1.61M | 173.67K | 58.93K | 50K | 1.75K | 0 | 0 | 1.75K | 0 | 0 |
| Gross Margin % | 62.5% | 69.04% | 75.26% | 62.04% | 52.02% | 44.49% | 70.03% | 69.92% | 43.97% | 56% | 62.65% | 66.34% | 100% | 2857.14% | 100% | - | - | 100% | - | - |
| Gross Profit Growth % | - | -6.57% | -26.38% | 32.51% | 72.2% | 50.9% | 278.07% | 218.02% | -10.8% | 12.39% | 824.36% | 194.72% | 17.86% | 2757.14% | - | - | -100% | - | - | - |
| Operating Expenses | 50.54M | 53.66M | 50.65M | 83.7M | 160.19M | 88.07M | 40.48M | 21.96M | 19.45M | 20.66M | 15.81M | 7.81M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| OpEx % of Revenue | - | 80.83% | 77.7% | 77.93% | 165.71% | 134.19% | 146.5% | 300.05% | 531.51% | 641.43% | 616.98% | 2981.87% | 10870.31% | 3095.09% | 3320.34% | - | - | 3289.83% | - | - |
| Selling, General & Admin | 40.69M | 38.28M | 42.04M | 70.08M | 69.88M | 55.81M | 31.06M | 19.24M | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 46.89K |
| SG&A % of Revenue | - | 57.67% | 64.49% | 65.25% | 72.29% | 85.03% | 112.41% | 262.82% | 484.48% | 546.55% | 344.41% | 1674.16% | 3982.01% | 2741.94% | 3320.34% | - | - | 3134.97% | - | - |
| Research & Development | 216K | 1.33M | 2.77M | 4.09M | 12.66M | 5.62M | 1.72M | 589.07K | 167.59K | 1.35M | 6.32M | 3.42M | 4.06M | 2.76M | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 2% | 4.25% | 3.81% | 13.1% | 8.57% | 6.23% | 8.05% | 4.58% | 41.84% | 246.63% | 1307.71% | 6888.3% | 157484% | - | - | - | - | - | - |
| Other Operating Expenses | 1.44M | 14.05M | 5.84M | 9.52M | 77.65M | 26.64M | 7.7M | 2.14M | 6.28M | 1.71M | 664.71K | 4.89K | 6.18K | 6.18K | 0 | 4.25K | 2.58K | 2.71K | 0 | 0 |
| Operating Income | -15.16M | -7.83M | -1.59M | -17.07M | -109.91M | -58.87M | -21.13M | -16.85M | -19.7M | -20.13M | -21.7M | -7.63M | -6.35M | -52.41K | -56.36K | -133.62K | -56.74K | -55.82K | -54.98K | -46.89K |
| Operating Margin % | -26.79% | -11.79% | -2.44% | -15.89% | -113.69% | -89.7% | -76.47% | -230.13% | -538.26% | -624.7% | -847.02% | -2915.53% | -10770.31% | -2995.09% | -3220.34% | - | - | -3189.83% | - | - |
| Operating Income Growth % | - | -391.95% | 90.68% | 84.47% | -86.69% | -178.6% | -25.43% | 14.49% | 2.11% | 7.28% | -184.37% | -20.25% | -12009.04% | 6.99% | 57.82% | -135.49% | -1.65% | -1.52% | -17.26% | - |
| EBITDA | -11.06M | -2.45M | 5.13M | -8.25M | -99.76M | -49.67M | -15.42M | -14.61M | -17.85M | -18.28M | -20.83M | -7.51M | -6.25M | -47.47K | -50.21K | -126.86K | -47.56K | -47.54K | -47.47K | -40.47K |
| EBITDA Margin % | -19.54% | -3.69% | 7.88% | -7.68% | -103.2% | -75.68% | -55.79% | -199.59% | -487.77% | -567.5% | -812.88% | -2870.37% | -10604.89% | -2712.69% | -2868.91% | - | - | -2716.51% | - | - |
| EBITDA Growth % | -650.97% | -147.72% | 162.23% | 91.73% | -100.85% | -222.17% | -5.52% | 18.16% | 2.35% | 12.23% | -177.21% | -20.24% | -13064.3% | 5.45% | 60.42% | -166.75% | -0.04% | -0.15% | -17.29% | - |
| D&A (Non-Cash Add-back) | 4.1M | 5.38M | 6.72M | 8.81M | 10.15M | 9.2M | 5.71M | 2.24M | 1.85M | 1.84M | 874.79K | 118.2K | 97.48K | 4.94K | 6.15K | 6.76K | 9.19K | 8.28K | 7.51K | 6.42K |
| EBIT | -30.32M | -10.04M | -5.32M | -12.09M | -38.1M | -38.24M | -17.92M | -16.85M | -17.84M | -19.97M | -22.69M | -7.63M | -57.49K | -52.41K | -56.36K | -133.62K | -56.47K | -55.82K | -54.98K | -46.89K |
| Net Interest Income | -2.24M | -3.7M | -4.79M | -4.96M | -147.48M | 0 | 0 | 0 | -749.42K | -2.53M | -5.49M | -114.99K | -4.23K | -4.9K | -3.32K | 0 | 0 | -3.07K | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.24M | 3.7M | 4.79M | 4.96M | 147.5M | 0 | 0 | 0 | 749.42K | 2.53M | 5.49M | 114.99K | 4.23K | 4.9K | 3.32K | 3.18K | 3.8K | 3.07K | 0 | 2.06K |
| Other Income/Expense | -18.51M | -5.92M | -8.79M | 14K | 1.02M | 840K | 7.51M | -10.29M | 9.51M | -2.38M | -6.48M | -114.99K | -4.23K | -4.9K | -3.32K | -3.18K | -3.53K | -3.07K | -2.19K | -2.06K |
| Pretax Income | -33.67M | -13.74M | -10.38M | -17.05M | -108.89M | -58.03M | -13.62M | -27.13M | -10.19M | -22.51M | -28.18M | -7.75M | -6.39M | -57.32K | -59.67K | -136.8K | -56.47K | -58.89K | -48.95K | -48.95K |
| Pretax Margin % | -59.49% | -20.71% | -15.92% | -15.88% | -112.64% | -88.42% | -49.29% | -370.64% | -278.36% | -698.67% | -1099.73% | -2959.45% | -10847.61% | -3275.31% | -3410% | - | - | -3365.37% | - | - |
| Income Tax | 447K | 437K | 2.14M | 0 | -110K | 259K | 0 | 20.04M | 0 | 0 | 0 | -23.91K | -813.7K | 0 | 0 | 0 | -548 | 0 | 2.19K | 0 |
| Effective Tax Rate % | -1.33% | -3.18% | -20.64% | 0% | 0.1% | -0.45% | 0% | -73.84% | 0% | 0% | 0% | 0.31% | 12.73% | 0% | 0% | 0% | 0.97% | 0% | -4.47% | 0% |
| Net Income | -34.05M | -13.56M | -15.84M | -17.05M | -108.78M | -58.29M | -13.62M | -47.17M | -10.19M | -22.51M | -28.18M | -7.72M | -5.58M | -57.32K | -59.67K | -136.8K | -60.27K | -58.89K | -57.17K | -48.95K |
| Net Margin % | -60.17% | -20.43% | -24.31% | -15.88% | -112.53% | -88.81% | -49.29% | -644.33% | -278.36% | -698.67% | -1099.73% | -2950.32% | -9466.8% | -3275.31% | -3410% | - | - | -3365.37% | - | - |
| Net Income Growth % | -2177.79% | 14.4% | 7.08% | 84.33% | -86.62% | -327.93% | 71.12% | -362.97% | 54.74% | 20.13% | -264.87% | -38.44% | -9632.88% | 3.95% | 56.38% | -126.98% | -2.34% | -3.01% | -16.79% | - |
| Net Income (Continuing) | -34.12M | -14.18M | -12.52M | -17.05M | -108.78M | -58.29M | -13.62M | -27.13M | -10.19M | -22.51M | -28.18M | -7.72M | -61.72K | -57.32K | -59.67K | -136.8K | -60.27K | -58.89K | -57.17K | -48.95K |
| Discontinued Operations | 62K | 620K | -3.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.24 | -2.16 | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1210.28 | -3061.23 | -193194.38 | -999999.00 | -551671.71 | -619854.44 | -7164.75 | -7459.37 | -17100.25 | -10045.00 | -11778.80 | -11434.60 | -48954.00 |
| EPS Growth % | -535.74% | 24.48% | 44.03% | 93.1% | -6.34% | -15.61% | 95.03% | 60.46% | 98.42% | 85.08% | -134.69% | 11% | -8551.45% | 3.95% | 56.38% | -70.24% | 14.72% | -3.01% | 76.64% | - |
| EPS (Basic) | - | -2.16 | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1210.28 | -3061.23 | -193194.38 | -999999.00 | -551671.71 | -619854.44 | -7164.75 | -7459.37 | -17100.25 | -10045.00 | -11778.80 | -11434.60 | -48954.00 |
| Diluted Shares Outstanding | 10.51M | 6.28M | 5.54M | 3.34M | 1.47M | 840K | 230K | 38.97K | 3.33K | 117 | 22 | 14 | 9 | 8 | 8 | 8 | 6 | 5 | 5 | 0 |
| Basic Shares Outstanding | 10.51M | 6.28M | 5.54M | 3.34M | 1.47M | 840K | 230K | 38.97K | 3.33K | 117 | 22 | 14 | 9 | 8 | 8 | 8 | 6 | 5 | 5 | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating leverage and scale
As reported in recent financial statements, AYTU's quarterly revenue has trended downward to $12.4M in 2026Q3, representing a significant contraction from the $18.7M peak observed in 2024Q2, suggesting that the company's core ADHD and specialty portfolio is struggling to maintain market share in a competitive landscape.
The consistent decline in top-line performance indicates that the company's strategic pivot toward high-margin CNS products has yet to yield the necessary volume growth to offset broader market pressures. Investors should monitor whether this revenue decay reflects a structural loss of competitive positioning or merely the impact of deprioritizing non-core consumer assets.
Based on the company's reported figures, gross margins have fluctuated significantly, dropping from a high of 77.9% in 2024Q2 to 55.1% in 2026Q3, which suggests that the firm faces mounting pressure from pharmacy benefit manager rebates and potential generic competition within its ADHD product lines.
The erosion of gross margin suggests that the company's pricing power is increasingly constrained by the current payor environment. This trend warrants further investigation into whether the ODT delivery technology still provides a sufficient barrier to entry or if the market is forcing a commoditization of these specialized formulations.
According to the income statement data, AYTU's operating expenses have remained stubbornly high relative to revenue, resulting in a negative operating margin of -32.7% in 2026Q3, which indicates that the company has failed to achieve the necessary scale to cover its fixed sales and marketing infrastructure.
The inability to scale operating income alongside gross profit suggests that the current sales force productivity is insufficient to support the existing cost base. Without a clear path to reducing SG&A intensity, the company appears to be trapped in a sub-scale operational cycle that continues to consume capital.
Analysis of the provided financial data reveals that AYTU's net income remains highly volatile and frequently negative, with a net margin of -45.3% in 2026Q3, highlighting the significant risk that the company's business model may not be viable without a fundamental restructuring of its cost structure.
Short-sellers would likely focus on the persistent cash burn and the lack of consistent profitability despite the high-margin nature of the underlying products. The reliance on non-operating items to occasionally bolster net income suggests that the core business remains fundamentally challenged by its current operational overhead.
Quick answers to the most common questions about buying AYTU stock.
For fiscal year 2025, Aytu BioPharma, Inc. (AYTU) reported total revenue of $66.4M.
Aytu BioPharma, Inc. (AYTU) reported a net loss of $13.6M for the fiscal year ending 2025.
Aytu BioPharma, Inc. (AYTU) reported an operating income of $-7.8M, resulting in an operating profit margin of -11.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Aytu BioPharma, Inc. (AYTU) generated $45.8M in gross profit for the year, representing a gross profit margin of 69.0%. This demonstrates the company's core pricing power and production efficiency.